CO6160322A2 - Derivados de quinazolinona e isoquinolinona acetamida - Google Patents

Derivados de quinazolinona e isoquinolinona acetamida

Info

Publication number
CO6160322A2
CO6160322A2 CO09036257A CO09036257A CO6160322A2 CO 6160322 A2 CO6160322 A2 CO 6160322A2 CO 09036257 A CO09036257 A CO 09036257A CO 09036257 A CO09036257 A CO 09036257A CO 6160322 A2 CO6160322 A2 CO 6160322A2
Authority
CO
Colombia
Prior art keywords
optionally substituted
6alkyl
6alkyloxy
halogen
hydroxy
Prior art date
Application number
CO09036257A
Other languages
English (en)
Inventor
Jeffrey Letourneau
Patrick Jokiel
Schulz Jurgen
Paul David Ratcliffe
Jeremiah Fiona
Duncan Robert Mcarthur
Michael Ohlmeyer
Koc-Kan Ho
Susan Elizabeth Napier
Original Assignee
Organon Nv
Pharmacopeia Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv, Pharmacopeia Llc filed Critical Organon Nv
Publication of CO6160322A2 publication Critical patent/CO6160322A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

1.- Un derivado de quinazolinona o isoquinolinona CARACTERIZADO porque tiene la fórmula I:dondeR1 es C1-6alquilo, C3-6cicloalquilo, C3-6cicloalquil-C1-3alquilo, C2-6alquenilo, C2-6alquinilo, estando dichos C1-6alquilo, C3-6cicloalquilo y C3-6cicloalquilo1-3alquilo opcionalmente sustituidos con hidroxi, C1-6alquiloxi, ciano o uno o más halógenos; R2 es C6-10arilo opcionalmente sustituido con uno a tres sustituyentes seleccionados entre halógeno, hidroxi, ciano, C1-6alquilo, C3-6cicloalquilo, C1-6alquiloxi y C3-6cicloalquiloxi, estando dichos C1-6alquilo, C3-6cicloalquilo, C1-6-alquiloxi y C3-6cicloalquiloxi opcionalmente sustituidos con uno o más halógenos; o R2 es un sistema de anillo heteroarilo de 5-10 miembros que comprende un heteroátomo seleccionado entre N, O y S, y está opcionalmente sustituido con un sustituyente seleccionado entre metilo, C1-6alquiloxi y halógeno; o R2 es C4-7cicloalquilo;R3 es un sustituyente opcional seleccionado entre C1-6alquilo, C1-6alquiloxi y halógeno, estando dichos C1- 6alquilo y C1-6alquiloxi opcionalmente sustituidos con uno o más halógenos; R4 es un grupo ubicado en la posición 6 ó 7 del anillo quinazolinona o isoquinolinona y tiene la fórmula II:dondeR5 junto con uno de R6 forman un anillo heterocíclico saturado o no saturado de 4-8 miembros que opcionalmente comprende una especie heteroatómica adicional seleccionada entre O, S y NR9, estando dicho anillo heterocíclico opcionalmente sustituido con uno o dos sustituyentes seleccionados entre metilo, halógeno, hidroxi y oxo, o R5 junto con uno de R7 y R8 forman un anillo heterocíclico de 6-8 miembros opcionalmente sustituido con uno o dos sustituyentes seleccionados entre metilo, halógeno, hidroxi y oxo; ...
CO09036257A 2006-09-11 2009-04-08 Derivados de quinazolinona e isoquinolinona acetamida CO6160322A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84371806P 2006-09-11 2006-09-11

Publications (1)

Publication Number Publication Date
CO6160322A2 true CO6160322A2 (es) 2010-05-20

Family

ID=39184483

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09036257A CO6160322A2 (es) 2006-09-11 2009-04-08 Derivados de quinazolinona e isoquinolinona acetamida

Country Status (20)

Country Link
US (1) US7820649B2 (es)
EP (1) EP2069315B1 (es)
JP (1) JP5256202B2 (es)
KR (1) KR20090107994A (es)
CN (1) CN101600698B (es)
AR (1) AR062731A1 (es)
AT (1) ATE523500T1 (es)
AU (1) AU2007296634B2 (es)
CA (1) CA2663161C (es)
CL (1) CL2007002635A1 (es)
CO (1) CO6160322A2 (es)
EC (1) ECSP099177A (es)
IL (1) IL197530A0 (es)
MX (1) MX2009002686A (es)
NO (1) NO20091012L (es)
NZ (1) NZ575426A (es)
PE (1) PE20080841A1 (es)
RU (1) RU2009113612A (es)
TW (1) TW200827352A (es)
WO (1) WO2008033764A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010229035A (ja) * 2007-08-01 2010-10-14 Taisho Pharmaceutical Co Ltd ピリドピリミジン−４−オン誘導体
WO2009130231A1 (en) * 2008-04-24 2009-10-29 Glaxo Group Limited Pyrrolo [1, 2-a] pyrazine derivatives as vasopressin vib receptor antagonists
JP5369721B2 (ja) * 2009-01-30 2013-12-18 大正製薬株式会社 ピリドピリミジン−４−オン誘導体
MX2012004289A (es) * 2009-10-13 2012-06-12 Msd Oss Bv Derivados de azina condensada para el tratamiento de enfermedades relacionadas con el receptor de acetilcolina.
WO2012043791A1 (ja) 2010-10-01 2012-04-05 大正製薬株式会社 １，２，４-トリアゾロン誘導体
MY168930A (en) 2011-10-27 2019-01-09 Taisho Pharmaceutical Co Ltd Azole derivative
SG11201406182PA (en) 2012-03-30 2014-10-30 Taisho Pharmaceutical Co Ltd Fused azole derivative
MA37756B1 (fr) 2012-06-13 2018-09-28 Hoffmann La Roche Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane
EP3590940B1 (en) 2012-09-25 2021-06-09 F. Hoffmann-La Roche AG Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
MA38982A1 (fr) 2013-11-26 2017-09-29 Hoffmann La Roche Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
MX2016010675A (es) 2014-03-26 2016-11-10 Hoffmann La Roche Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa).
US10030010B2 (en) 2014-08-04 2018-07-24 Sandoz Ag Route of synthesis for the preparation of suvorexant
WO2016034703A1 (en) 2014-09-05 2016-03-10 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
MA41898A (fr) * 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CN108026077B (zh) 2015-09-04 2021-11-05 豪夫迈·罗氏有限公司 苯氧基甲基衍生物
MA42923A (fr) 2015-09-24 2021-04-28 Hoffmann La Roche Composés bicycliques comme inhibiteurs mixtes de atx/ca
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
WO2017050792A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
JP6845230B2 (ja) 2015-09-24 2021-03-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ デュアルａｔｘ／ｃａ阻害剤としての新規な二環式化合物
LT3386591T (lt) * 2015-12-09 2020-10-12 Cadent Therapeutics, Inc. Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas
EP3386990B1 (en) 2015-12-09 2023-04-19 Novartis AG Thienopyrimidinone nmda receptor modulators and uses thereof
EP3558318B1 (en) 2016-12-22 2023-12-20 Novartis AG Nmda receptor modulators and uses thereof
MA49879A (fr) 2017-03-16 2020-06-24 Hoffmann La Roche Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
IL280474B2 (en) 2018-08-03 2023-09-01 Cadent Therapeutics Inc Heteroaromatic nmda receptor modulators and their uses
CN111100063B (zh) * 2018-10-25 2022-05-17 南京药石科技股份有限公司 一种合成2-氟甲基取代的吡咯烷、哌啶以及哌嗪衍生物的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2506767A1 (fr) 1981-05-26 1982-12-03 Synthelabo Derives heterocycliques d'amidoximes, leur preparation et leur application en therapeutique
CA2288140C (en) 1997-04-25 2007-04-03 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
IL139199A (en) 1999-11-02 2006-10-31 Nihon Nohyaku Co Ltd Derivatives of aminoquinazolinone (thion) or their salts, their intermediates, pesticides and method of use
FR2804114B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2842527B1 (fr) 2002-07-19 2005-01-28 Sanofi Synthelabo Derives d'acyloxypyrolidine, leur preparation et leur application en therapeutique
KR100843053B1 (ko) * 2004-01-16 2008-07-01 에프. 호프만-라 로슈 아게 중추 신경계 질환의 치료를 위한 5-하이드록시트립트아민수용체(5-ｈｔ)의 조절제로서1-벤질-5-피페라진-1-일-3,4-다이하이드로-1ｈ-퀴나졸린-2-온 유도체 및 각각의1ｈ-벤조(1,2,6)티아다이아진-2,2-다이옥사이드 및1,4-다이하이드로-벤조(ｄ)(1,3)옥사진-2-온 유도체
CN1960977B (zh) * 2004-05-31 2010-07-21 万有制药株式会社 喹唑啉衍生物
WO2006012577A2 (en) * 2004-07-22 2006-02-02 Bayer Pharmaceuticals Corporation Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
TW200643015A (en) * 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
MX2009002685A (es) * 2006-09-11 2009-10-13 Organon Nv Derivados de acetamida de (2- (1-oxo-1h-isoquinolin-2-il).

Also Published As

Publication number Publication date
CA2663161A1 (en) 2008-03-20
US7820649B2 (en) 2010-10-26
CL2007002635A1 (es) 2009-10-23
EP2069315A2 (en) 2009-06-17
JP2010502746A (ja) 2010-01-28
CA2663161C (en) 2014-10-28
RU2009113612A (ru) 2010-10-20
NO20091012L (no) 2009-03-26
CN101600698A (zh) 2009-12-09
AU2007296634A1 (en) 2008-03-20
NZ575426A (en) 2010-09-30
CN101600698B (zh) 2012-01-11
WO2008033764A3 (en) 2008-12-18
EP2069315B1 (en) 2011-09-07
MX2009002686A (es) 2009-10-13
AR062731A1 (es) 2008-11-26
KR20090107994A (ko) 2009-10-14
US20080090802A1 (en) 2008-04-17
TW200827352A (en) 2008-07-01
WO2008033764A2 (en) 2008-03-20
IL197530A0 (en) 2009-12-24
JP5256202B2 (ja) 2013-08-07
ECSP099177A (es) 2009-06-30
AU2007296634B2 (en) 2012-09-20
ATE523500T1 (de) 2011-09-15
PE20080841A1 (es) 2008-06-14
EP2069315A4 (en) 2010-11-03

Similar Documents

Publication Publication Date Title
CO6160322A2 (es) Derivados de quinazolinona e isoquinolinona acetamida
AR119651A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
AR054365A1 (es) Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos.
PE20161021A1 (es) Derivados heterociclicos biciclicos como inhibidores de bromodominio
AR057209A1 (es) Compuestos para el tratamiento de trastornos inflamatorios y enfermedades microbianas
PE20181067A1 (es) Conjugados de anticuerpo-farmaco de pirrolobenzodiazepina y metodos de uso
CL2009000323A1 (es) Compuestos derivados de heterociclos no condensados sustituidos, inhibidores de la funcion de la proteina ns5a; composicion farmaceutica que los comprende; y su uso para tratar la infeccion del virus de la hepatitis c.
AR040271A1 (es) Derivados de benzimidazol
AR049319A1 (es) Derivados de 6-heteroarilfenantridinas
AR074596A1 (es) Derivados de (3-oxo) piridazin-4-ilurea
AR040047A1 (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6
PE20171240A1 (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
AR061548A1 (es) 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii.
AR088449A1 (es) Benzilindazoles sustituidos
PA8843701A1 (es) Derivados de indolina y métodos para usarlos
AR054799A1 (es) Derivados de oxindol
AR055620A1 (es) Derivados de cicloalcano-carboxamidas
CO6150158A2 (es) Piperidinas sustituidas que aumentan la actividad de p53 y su uso
AR059513A1 (es) Derivados benzoil - piperidina como moduladores de 5ht/ d3
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR059338A1 (es) N-fenilbenzotriazolilo como inhibidores de c-kit
PE20170323A1 (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
AR069436A1 (es) Compuestos de piridina
AR097866A1 (es) Derivados de 4-azaindol